Trevi Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference
April 07 2021 - 7:30AM
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage
biopharmaceutical company focused on the development and
commercialization of Haduvio™ (nalbuphine ER) to treat serious
neurologically mediated conditions, today announced that management
will participate in a virtual fireside chat, as well as host
investor meetings, at the 20th Annual Needham Virtual Healthcare
Conference on April 14, 2021. Trevi’s presentation is scheduled for
2:15 p.m. ET.
A live webcast of the virtual fireside chat can be
accessed by visiting ‘News & Events’ in the ‘Investors &
News’ section on the Company’s website at
www.trevitherapeutics.com. An archived replay of the webcast will
also be available for 30 days on the Company’s website following
the conference.
The Company’s corporate presentation is posted to
its website in the ‘Investors & News’ section under ‘News &
Events’.
About Trevi Therapeutics,
Inc.Trevi Therapeutics, Inc. is a clinical-stage
biopharmaceutical company focused on the development and
commercialization of Haduvio to treat serious neurologically
mediated conditions. Trevi is conducting a Phase 2b/3
clinical trial of Haduvio for the treatment of chronic pruritus
associated with prurigo nodularis and a Phase 2 trial for chronic
cough in patients with idiopathic pulmonary fibrosis (IPF). Trevi
is also developing Haduvio for the treatment of levodopa-induced
dyskinesia (LID) in patients with Parkinson’s disease and is in the
planning stages of a Phase 2 study in this indication. These
conditions share a common pathophysiology that is mediated through
opioid receptors in the central and peripheral nervous systems.
Founded in 2011, Trevi Therapeutics is
headquartered in New Haven, CT.
About HaduvioHaduvio is an oral
extended release formulation of nalbuphine. Nalbuphine is a mixed
ĸ-opioid receptor agonist and µ-opioid receptor antagonist that has
been approved and marketed as an injectable for pain indications
for more than 20 years in the United
States and Europe. The ĸ- and µ-opioid receptors are
known to be critical mediators of itch, cough and certain movement
disorders. Nalbuphine’s mechanism of action also mitigates the risk
of abuse associated with µ-opioid agonists because it antagonizes,
or blocks, µ-opioid receptors. Nalbuphine is currently the only
opioid approved for marketing that is not classified as a
controlled substance in the United States and most
of Europe. Trevi intends to propose Haduvio as the
trade name for the nalbuphine ER investigational product. Haduvio
is an investigational drug product and its safety and efficacy have
not been fully evaluated by any regulatory authority.
Investor ContactKatie McManusTrevi
Therapeutics,
Inc.203-304-2499katie.mcmanus@trevitherapeutics.com
Media Contact Rosalia
Scampoli914-815-1465rscampoli@marketcompr.com
Trevi Therapeutics (NASDAQ:TRVI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Trevi Therapeutics (NASDAQ:TRVI)
Historical Stock Chart
From Apr 2023 to Apr 2024